Literature DB >> 22244923

Opposite effects of low versus high dose haloperidol treatments on spontaneous and apomorphine induced motor behavior: evidence that at a very low dose haloperidol acts as an indirect dopamine agonist.

Flávia Regina Cruz Dias1, Liana Wermelinger de Matos, Maria de Fátima dos Santos Sampaio, Robert J Carey, Marinete Pinheiro Carrera.   

Abstract

Anti-psychotic drugs are antagonists at the dopamine D2 receptors and repeated administration can lead to the development of dopamine receptor supersensitivity. In two experiments, separate groups of rats were administered 10 daily low or high doses of the typical anti-psychotic drug haloperidol (0.03 or 1.0 mg/kg). The high dose decreased locomotion whereas, the low dose increased locomotion. After 5 days of withdrawal, all groups received 2.0 mg/kg apomorphine on 5 successive days. The apomorphine treatments given to the vehicle group generated a progressive locomotion sensitization effect and this effect was potentiated by pre-exposure to 0.03 mg/kg haloperidol. Initially, the prior high dose of haloperidol exaggerated the apomorphine locomotor stimulant effect but with repeated apomorphine treatments desensitization developed. Following a 5-day withdrawal period an apomorphine challenge test was conducted and apomorphine sensitization was absent in the haloperidol high dose pre-exposure group but potentiated in the low dose pre-exposure group. In the second replication experiment a conditioning test instead of a sensitization challenge test was conducted 5 days after completion of the 5-day apomorphine treatment protocol. The repeated apomorphine treatments induced conditioned hyper- locomotion and this conditioned effect was prevented by the prior high dose haloperidol pre-exposure but enhanced by the prior low dose haloperidol pre-exposure. Two new key findings are (a) that a low dose haloperidol regimen can function as a dopamine agonist and these effects persist after withdrawal and (b) that repeated apomorphine treatments can desensitize D2 receptors previously sensitized by a high dose haloperidol treatment regimen.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22244923     DOI: 10.1016/j.bbr.2011.12.042

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  12 in total

1.  Residual dopamine receptor desensitization following either high- or low-dose sub-chronic prior exposure to the atypical anti-psychotic drug olanzapine.

Authors:  Flávia Regina Cruz Dias; Liana Wermelinger de Matos; Maria de Fátima Dos Santos Sampaio; Robert J Carey; Marinete Pinheiro Carrera
Journal:  Psychopharmacology (Berl)       Date:  2012-07-24       Impact factor: 4.530

2.  Xanthohumol Pyrazole Derivative Improves Diet-Induced Obesity and Induces Energy Expenditure in High-Fat Diet-Fed Mice.

Authors:  Ines L Paraiso; Luce M Mattio; Armando Alcázar Magaña; Jaewoo Choi; Layhna S Plagmann; Margaret A Redick; Cristobal L Miranda; Claudia S Maier; Sabrina Dallavalle; Chrissa Kioussi; Paul R Blakemore; Jan F Stevens
Journal:  ACS Pharmacol Transl Sci       Date:  2021-11-04

3.  The Arousal-motor Hypothesis of Dopamine Function: Evidence that Dopamine Facilitates Reward Seeking in Part by Maintaining Arousal.

Authors:  Marcin Kaźmierczak; Saleem M Nicola
Journal:  Neuroscience       Date:  2022-07-16       Impact factor: 3.708

4.  Animal Models of Psychosis: Current State and Future Directions.

Authors:  Alexandra D Forrest; Carlos A Coto; Steven J Siegel
Journal:  Curr Behav Neurosci Rep       Date:  2014-06-01

5.  Opposite effects of typical and atypical anti-psychotic drugs on sensitized dopamine receptors: sub-chronic low dose Olanzapine exposure reverses sensitization but a similar regimen of low dose haloperidol potentiates sensitization effects.

Authors:  Flávia Regina Cruz Dias; João Marcos de Mello Bastos; Maria de Fátima Dos Santos Sampaio; Robert J Carey; Marinete Pinheiro Carrera
Journal:  Psychopharmacology (Berl)       Date:  2013-07-12       Impact factor: 4.530

6.  A Natural Product with High Affinity to Sigma and 5-HT7 Receptors as Novel Therapeutic Drug for Negative and Cognitive Symptoms of Schizophrenia.

Authors:  Lien Wang; Yan Zhang; Chaoran Wang; Xiuli Zhang; Zhiwei Wang; Xinmiao Liang; Amal Alachkar; Olivier Civelli
Journal:  Neurochem Res       Date:  2019-09-16       Impact factor: 3.996

7.  Parkinson's disease: low-dose haloperidol increases dopamine receptor sensitivity and clinical response.

Authors:  Craig J Hudson; Philip Seeman; Mary V Seeman
Journal:  Parkinsons Dis       Date:  2014-11-20

8.  Temporal Factors Modulate Haloperidol-Induced Conditioned Catalepsy.

Authors:  Lucía Cárcel; Luis G De la Casa
Journal:  Front Behav Neurosci       Date:  2021-07-02       Impact factor: 3.558

Review 9.  The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future.

Authors:  Manon Auffret; Sophie Drapier; Marc Vérin
Journal:  Drugs R D       Date:  2018-06

10.  Conditioned increase of locomotor activity induced by haloperidol.

Authors:  Luis Gonzalo De la Casa; Lucía Cárcel; Juan Carlos Ruiz-Salas; Lucía Vicente; Auxiliadora Mena
Journal:  PLoS One       Date:  2018-10-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.